Are Wegovy tablets available on the NHS? The honest answer

# Are Wegovy tablets available on the NHS? The honest answer

The short answer is no. As of June 2026, oral Wegovy — the semaglutide tablet approved by the MHRA on 11 June 2026 — is not available on the NHS. It is currently only accessible via private prescription through GPhC-registered UK providers. For many people hoping for NHS access, that is a disappointing reality. But understanding why, and what the realistic path to NHS availability looks like, can help you make informed decisions about your options right now.

> **Important:** Wegovy tablets are a prescription-only medicine. Always consult a qualified healthcare professional before starting or changing treatment.

—

## What is available on the NHS — and what is not

It is worth being precise here, because there are two distinct forms of Wegovy and they are treated very differently by the NHS.

**Wegovy injection** (subcutaneous semaglutide 2.4mg, weekly) received a positive NICE recommendation for NHS use in 2023. However, access remains extremely limited. It is only commissioned for patients with a BMI of 40 or above — or 35 and above alongside severe comorbidities such as type 2 diabetes or cardiovascular disease. Even for eligible patients, treatment is only available through specialist NHS Tier 3 and Tier 4 weight management services, many of which have referral waiting times of 12 months or more. In practice, the injectable form is theoretically on the NHS but functionally inaccessible for most people who might benefit from it.

**Wegovy tablets** (oral semaglutide) have not been through the NICE evaluation process at all. The MHRA only granted approval on 11 June 2026. NICE will not have even begun its health technology appraisal yet.

—

## Why NHS availability takes years after MHRA approval

When a new medicine receives MHRA approval, that approval means it is safe and effective enough to be used in clinical practice in the UK. It does not mean the NHS will fund it, or that GPs can prescribe it on the NHS. Those are entirely separate questions determined by a different body: the National Institute for Health and Care Excellence.

The NICE process works roughly as follows:

1. The drug manufacturer (in this case Novo Nordisk) submits a dossier to NICE requesting a health technology appraisal
2. NICE commissions an evidence review — typically from an academic centre — to assess whether the treatment represents value for money for the NHS
3. NICE appraises the evidence and consults stakeholders including patients, clinicians, and the manufacturer
4. NICE publishes draft guidance, allows for appeals, then issues final guidance
5. If guidance is positive, NHS commissioners are legally required to make the treatment available within 90 days

Each step takes time. The full process from submission to final guidance typically runs 18 to 24 months — and that clock does not start until the manufacturer submits, which may be some months after MHRA approval.

—

## What is the realistic timeline for NHS Wegovy tablet access?

Based on the standard NICE timetable, the earliest plausible date for NHS-funded oral Wegovy would be late 2028. A more realistic estimate, accounting for typical delays and the need for submissions to be prepared and reviewed, points to 2029 or 2030.

That is not a criticism of the process — thorough evaluation of cost-effectiveness is exactly what should happen before a health system commits to funding a new long-term treatment for a large patient population. But it is important to be honest that anyone hoping to access oral Wegovy on the NHS in 2026 or 2027 is likely to be disappointed.

There is also no guarantee of a positive NICE recommendation. NICE evaluates treatments against a cost-effectiveness threshold of roughly £20,000 to £30,000 per quality-adjusted life year gained. Injectable Wegovy cleared this threshold with certain restrictions. Whether oral Wegovy will do so at its current private pricing will depend on the evidence presented and the price Novo Nordisk negotiates with NHS England. That negotiation is a confidential process and will not be visible publicly.

—

## How NICE assesses cost-effectiveness

NICE does not simply ask whether a medicine works. It asks whether it works well enough to justify the cost compared to existing treatments. For weight management, existing NHS options include dietary support, behavioural programmes, and older medicines such as orlistat — none of which achieve anywhere near the 15.1% average weight loss seen in the OASIS 2 trial with oral semaglutide at 25mg.

The NICE appraisal of injectable Wegovy in 2023 took the weight loss data seriously and gave a positive recommendation — but with restrictions intended to focus NHS spending on those with the greatest need. A similar approach is likely for oral Wegovy if NICE proceeds with a positive outcome: approval for NHS use, but limited to specific BMI thresholds and clinical criteria.

Historical precedent with injectable GLP-1 receptor agonists suggests NICE is generally supportive of this class of medicine where the clinical evidence is strong. The OASIS 2 data is strong. But this is not a guarantee, and the price negotiations between Novo Nordisk and NHS England will matter enormously.

—

## What are your options if you cannot access NHS treatment?

If you need treatment now and NHS access is not available to you, the options are as follows.

**Private prescription through a GPhC-registered provider.** This is the route most people considering oral Wegovy in 2026 will take. Prices range from £64 per month (Bolt Pharmacy, at the starting 1.5mg dose) to £113.95 per month (Pharmacy2U), before dose escalation. Use CompareWegovyPrices.co.uk to compare verified current prices across all seven providers with pre-orders open. All seven are GPhC registered and offer free delivery.

**NHS Tier 3 weight management referral.** If you meet the eligibility criteria (BMI 40+, or 35+ with comorbidities), you can ask your GP for a referral to a specialist NHS weight management service. Wait times are long and availability is patchy by region, but this is the legitimate NHS pathway that exists today. Note that this service would offer injectable Wegovy or other treatments — not the tablet.

**Watchful waiting.** If private costs are not manageable right now, keeping an eye on the NICE process and setting up a price alert through CompareWegovyPrices.co.uk means you will be informed when NHS access becomes available or private prices change.

—

## Does having a private prescription improve your chances of NHS access later?

No. Private and NHS prescription pathways are entirely separate. Having a private prescription for oral Wegovy does not place you higher in any NHS queue, does not count as clinical evidence for your NHS file, and does not create any fast track to NHS funding. If and when NHS Wegovy tablets become available, you would need to go through the standard NHS eligibility and referral process regardless of your private treatment history.

—

## The broader NHS GLP-1 landscape

It is worth placing oral Wegovy in context. The NHS is managing significant demand pressure across the GLP-1 receptor agonist category. Tirzepatide (Mounjaro), approved by NICE for NHS use in weight management in early 2025, is already in the system. Injectable semaglutide supply constraints affected the NHS in 2024 and 2025. NHS England has been managing GLP-1 prescribing carefully, with central guidance to prescribing bodies about which patients should be prioritised.

Oral Wegovy will enter this landscape as a new option — one with compelling efficacy data, a more convenient administration route, and potentially strong patient preference data. Whether that translates into a swift NICE recommendation and NHS commissioning is a question only time and Novo Nordisk’s submission will answer.

—

## Frequently asked questions

### Can my GP prescribe oral Wegovy on the NHS right now?

No. Oral Wegovy has not been through the NICE health technology appraisal process and is not commissioned for NHS use. GPs cannot prescribe it on an NHS prescription. It is only available via private prescription through GPhC-registered providers.

### Is injectable Wegovy available on the NHS?

Yes, in principle — but access is extremely restricted. Injectable Wegovy (subcutaneous semaglutide 2.4mg) was approved by NICE for NHS use in 2023, but only for patients with a BMI of 40 or above (or 35 with severe comorbidities) who are being treated within specialist NHS weight management services. Waiting times for those services are typically 6 to 12 months or longer.

### When will NICE review oral Wegovy?

NICE has not announced a timeline for reviewing oral semaglutide tablets. The process cannot begin until Novo Nordisk submits a dossier requesting an appraisal. Based on the standard 18-to-24-month NICE process, the earliest realistic date for NHS availability would be late 2028 at the very earliest.

### Will NICE definitely approve oral Wegovy for NHS use?

Nothing is certain. NICE assesses cost-effectiveness, not just clinical effectiveness. The OASIS 2 trial data is strong, and NICE has previously recommended injectable semaglutide, but the oral version will be evaluated on its own merits and at whatever price Novo Nordisk negotiates with NHS England. A positive recommendation is plausible but not guaranteed.

### If I pay privately now, will the NHS reimburse me later?

No. The NHS does not reimburse private prescriptions. Private and NHS pathways are entirely separate. There is no mechanism to reclaim private costs if the treatment later becomes available on the NHS.

### How much does oral Wegovy cost privately while I wait for NHS access?

Starting prices range from £64 per month (Bolt Pharmacy) to £113.95 per month (Pharmacy2U) at the 1.5mg starting dose. Note that costs increase as your dose escalates through the schedule. CompareWegovyPrices.co.uk publishes verified, up-to-date prices across all seven UK providers with pre-orders open as of June 2026.

—

*This article is for informational purposes only and does not constitute medical advice. Oral Wegovy (semaglutide) is a prescription-only medicine available in the UK. Always consult a registered UK healthcare professional before starting any weight management treatment. CompareWegovyPrices.co.uk is not affiliated with Novo Nordisk.*